Mouwasat Medical Services stock
Price history
−20.14% over the period1 year: from SAR 71.00 (November 23, 2025) to SAR 56.70 (November 22, 2026), −20.14%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 22, 2026 | SAR 56.70 |
| October 29, 2026 | SAR 55.20 |
| September 30, 2026 | SAR 61.45 |
| August 31, 2026 | SAR 65.35 |
| July 30, 2026 | SAR 62.20 |
| June 30, 2026 | SAR 63.75 |
| May 31, 2026 | SAR 65.35 |
| April 30, 2026 | SAR 68.00 |
| March 31, 2026 | SAR 72.65 |
| February 26, 2026 | SAR 63.65 |
| January 29, 2026 | SAR 69.60 |
| December 31, 2025 | SAR 66.65 |
| November 30, 2025 | SAR 68.00 |
| November 23, 2025 | SAR 71.00 |
At a glance
The company
Operates a network of hospitals and medical centers providing specialized healthcare services and pharmaceuticals across Saudi Arabia
Latest results
Quarter to September 30, 2026 · EPS SAR 0.96 (estimate SAR 0.99)
Next event
TickerLandia's take on Mouwasat Medical Services
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 14 vs a median of 26 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 14 vs 28 (−51%) in a group of 10.
- Strong point: Financial strength (93/100 in its group). Weak point: Market momentum (23/100).
- “Best dividend stocks” (Saudi Arabia): No. 1 of 4.
- “Below historical valuation” (Saudi Arabia): No. 3 of 17.
- “Most upside for analysts” (Saudi Arabia): No. 5 of 33.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−23.60% from the 52-week high
Analysts · 13 analysts
Average targetSAR 75.92+34.37% vs. price
Buy 6 · Hold 6 · Sell 1 · Buy
TickerLandia Fingerprint: Mouwasat Medical Services
Compared with similar companies: very high financial strength and very high profitability.
Financials and price compared with 19 companies in the medical care facilities industry, worldwide. Momentum and risk compared with 46 Middle Eastern stocks.
Priceaverage41
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 13.5 31 Forward P/E 13.1 31 EV/EBITDA 10.9 39 Price/book 2.77 38 Price/sales 3.33 66 Profitabilityvery high80
How much it earns on revenue and capital.
Metric Value Position in group ROA 8.8% 82 Gross margin 40.6% 55 Operating margin 25.8% 97 Net margin 24.3% 97 ROE 21.2% 69 Earnings stabilityaverage59
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.6% 61 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 58 Growthaverage55
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +10.20% 71 Earnings growth (year over year) −5.80% 39 Average revenue growth (3 years) +11.35% 55 Financial strengthvery high93
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.29 97 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.44 92 Interest coverage 44.9 92 Current ratio 1.72 92 Dividendhigh79
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 3.7% 85 Payout ratio 73.5% 85 Consecutive dividend years at least 17 years 67 Market momentumweak23
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −18.74% 23 Distance from 200-day average −10.55% 23 Riskaverage43
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 27.3% 58 Volatility (60 days) 23.7% 29
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Mouwasat Medical Services is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Mouwasat Medical Services's P/E today is 13.8, below the median of its last 10 fiscal years (26.2; between 16.2 and 34.9 from 2016 to 2025). Mouwasat Medical Services's P/E (trailing 12 months): 13.5, −51% against the median of a group of 10 similar companies (27.7).
Compared with 10 similar companies
| Metric | Mouwasat Medical Services | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 13.5 | Middle | |
| Forward P/E | 13.1 | Middle | |
| Operating margin | 25.8% | High | |
| ROE | 21.2% | High | |
| Debt/equity | 0.29 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Mouwasat Medical Services. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
SAR 856.37M
Latest quarter · Q3 2026
Net income
SAR 188.01M
Latest quarter · Q3 2026
Quarterly net margin
22.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- SAR 11.49B
- P/E
- 13.5
- EPS
- SAR 4.25
- Volume
- 126.76K
- Daily trading
- €2.96M
- Dividend yield
- 5.53%
- Last ex-dividend on October 18, 2026
How Mouwasat Medical Services is changing
All resultsRevenue grew 9.5% a year on average over the last 5 years
Operating margin fell from 28.8% to 27.3%
Profits turn into cash: free cash flow equal to 100% of net income
Returns
Mouwasat Medical Services returns with dividends
SAR 1,000 invested in Mouwasat Medical Services 5 years ago, on November 22, 2021, would be worth SAR 770 today with dividends reinvested: −23.01% in total, −5.10% per year. On price alone it would be SAR 687 (−31.27%).
| Period | Mouwasat Medical Services | SAR 1,000 becomes |
|---|---|---|
| 1 month | +2.16% | SAR 1,022 |
| 6 months | −14.59% | SAR 854 |
| Year to date | −14.93% | SAR 851 |
| 1 year | −16.23% | SAR 838 |
| 3 years | −44.62% | SAR 554 |
| 5 years | −23.01% | SAR 770 |
| 10 years | +119.83% | SAR 2,198 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Mouwasat Medical Services: technical analysis
Mouwasat Medical Services is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 60.3% below its all-time closing high (SAR 142.40, April 21, 2024).
- Trend
- Downward
- RSI (14 sessions)
- 44
- Between 30 and 70
- vs 200-session average
- −11.96%
Support and resistance
Price areas where Mouwasat Medical Services has stopped several times in the last year. They describe the chart; they are not forecasts.
- ResistanceSAR 64.40+13.98%3 touches, last on June 11, 2026
- ResistanceSAR 60.92+7.83%2 touches, last on October 1, 2026
- ResistanceSAR 59.55+5.40%2 touches, last on November 15, 2026
- Last priceSAR 56.50
- SupportSAR 52.75−6.64%2 touches, last on November 3, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 23.8%
- Largest fall in the last year
- −27.33%
Close of November 22, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Mouwasat Medical Services: seasonality
Average monthly price change over 18 years
Over the last 18 years, the strongest month for Mouwasat Medical Services has been April: +5.43% on average, positive in 13 years out of 17. The weakest has been August: −2.64% on average, positive in 6 years out of 17. November, the current month, has been positive in 8 years out of 17 (−0.94% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.15% | −2.04% | 7 of 17 |
| February | +0.84% | +1.46% | 10 of 17 |
| March | +5.31% | +4.25% | 11 of 17 |
| April | +5.43% | +5.02% | 13 of 17 |
| May | −1.60% | −1.51% | 8 of 17 |
| June | +1.87% | 0.00% | 8 of 17 |
| July | +4.61% | +0.73% | 11 of 17 |
| August | −2.64% | −4.88% | 6 of 17 |
| September | −1.92% | −2.12% | 7 of 17 |
| October | −0.08% | +0.19% | 9 of 18 |
| November | −0.94% | 0.00% | 8 of 17 |
| December | +4.09% | +6.53% | 12 of 17 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Mouwasat Medical Services and its competitors
Patients across Saudi Arabia form the core customer base of Mouwasat Medical Services Company, which runs a network of hospitals and specialized centers for eye care, obesity treatment, cardiology, diabetes, robotic surgery, fertility, rehabilitation, long-term care, stroke and skincare. Its services also include inpatient pharmacy, intravenous medication preparation, chemotherapy preparation and clinical pharmacy.
- Headquarters
- Dammam, Saudi Arabia
- Employees
- 2,389
- Founded
- 1974
- Chief executive
- Nasser Sultan Al-Subaie
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Mouwasat Medical Services4002 | $3.16B | 25.8% | 13.5 | −14.59% |
| Dr. Sulaiman Al Habib Medical Services Group4013 | $20.02B | 18.6% | 29.1 | −6.43% |
| MedicoverMCOV.B | $3.82B | 7.4% | 38.3 | +19.86% |
| Fortis HealthcareFORTIS | $6.47B | 17.1% | 56.8 | −15.35% |
| Spire Healthcare GroupSPI | $1.3B | 7.6% | — | +12.90% |
| Ramsay Health CareRHC | $8.37B | 5.9% | 40.0 | +40.77% |
Same industry or related industries, similar size. Compare Mouwasat Medical Services with its competitors · Full profile
